drugset / Trial / NCT01522950

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study comparing the efficacy of nebivolol and atenolol at improving small artery elasticity and reducing cardiovascular disease risk in subjects with early vascular disease. Approximately 75 subjects with borderline/elevated blood pressures and impaired endothelial function, as measured by arterial elasticity scores, will be recruited and assigned to treatment groups using a block randomization scheme. Patients will be randomly allocated to nebivolol, atenolol or placebo, and then followed for 9 months.

Timeline

Start
2010-05
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atenolol Other / unclassified 50 mg
Comparator Nebivolol Other / unclassified 10 mg

Indications